On December 2, pharmaceutical giant GlaxoSmithKline quietly halted a clinical trial of SRT501, a concentrated form of resveratrol, which is the much-hyped substance found in red wine grapes.
The reason this matters is that SRT501 had been one of the most closely watched molecules in the Big Pharma pipeline ever since 2008, when GlaxoSmithKline snapped it up in a $720 million acquisition of Sirtris Pharmaceuticals — the company that first suggested resveratrol might be useful for treating age-related diseases.